Literature DB >> 32322920

[Intensity-modulated fractionated radiotherapy vs. stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomized, open-label, phase 3, noninferiority trial].

Gerhard G Grabenbauer1.   

Abstract

Entities:  

Year:  2020        PMID： 32322920     DOI： 10.1007/s00066-020-01616-w

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  2 in total

1.  Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Authors:  Jeff M Michalski; Jennifer Moughan; James Purdy; Walter Bosch; Deborah W Bruner; Jean-Paul Bahary; Harold Lau; Marie Duclos; Matthew Parliament; Gerard Morton; Daniel Hamstra; Michael Seider; Michael I Lock; Malti Patel; Hiram Gay; Eric Vigneault; Kathryn Winter; Howard Sandler
Journal:  JAMA Oncol       Date:  2018-06-14       Impact factor: 31.777

2.  Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Authors:  Douglas H Brand; Alison C Tree; Peter Ostler; Hans van der Voet; Andrew Loblaw; William Chu; Daniel Ford; Shaun Tolan; Suneil Jain; Alexander Martin; John Staffurth; Philip Camilleri; Kiran Kancherla; John Frew; Andrew Chan; Ian S Dayes; Daniel Henderson; Stephanie Brown; Clare Cruickshank; Stephanie Burnett; Aileen Duffton; Clare Griffin; Victoria Hinder; Kirsty Morrison; Olivia Naismith; Emma Hall; Nicholas van As
Journal:  Lancet Oncol       Date:  2019-09-17       Impact factor: 41.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.